Webinar | Microfluidics Technology in Viral Detection and Infectious Disease Research

Microfluidics Technology in Viral Detection and Infectious Disease Research

In a short period of time, a novel coronavirus (SARS-CoV-2) has impacted our lives, society and health care infrastructure. In today's online seminar, we will provide examples of how Fluidigm products are supporting global laboratory efforts in response to COVID-19 to address critical needs for testing and clinical research by delivering:

  • Versatile automated microfluidic systems that support multiple biomarker types (DNA, RNA and protein)
  • Scalable throughput that enables the testing of more than 6,000 samples per day, with multiple targets of interest per sample
  • Flexible panel designs that enable users to easily add, remove or change assays without changing technologies
  • Cost-efficient workflows that minimize reagent consumption using microfluidics technology

During this webinar, we will explore how Fluidigm multi-omic solutions help enable interrogation of health and disease in comprehensive new ways. Whether you are seeking to gain new insights into coronavirus (SARS-CoV-2) viral detection or infectious disease research, or to accelerate therapeutic development, we can help you reach your goal.



About the presenters:

Bill Hunt, MS

Bill Hunt, MS
Director, Microfluidics Product Management,
Fluidigm

Steve Kain

Steve Kain, PhD, MBA
Director, Genomics Product Management,
Fluidigm

Luke Stewart

Luke Stewart
Senior Manager, Field Applications,
Fluidigm

For Research Use Only. Not for use in diagnostic procedures.